Table S2 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Kazuhiko Nakagawa, Ernest Nadal,Edward B. Garon, Makoto Nishio,Takashi Seto,Nobuyuki Yamamoto,Keunchil Park, Jin‐Yuan Shih,Luis Paz‐Ares,Bente Frimodt‐Moller,Annamaria H. Zimmermann,Sameera R. Wijayawardana,Carla Visseren‐Grul,Martin Reck

openalex（2023）

Cited 0|Views0

No score

Abstract

Treatment-emergent adverse events (occurring in 20% or more patients) and adverse events of special interest by baseline EGFR-activating mutation subgroup (safety population).

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined